Biogen Inc.
BIIBBiogen’s future hinges on whether its next generation of neurology drugs can offset the steady erosion of its older multiple sclerosis franchise.
Because this is a cash-rich drug maker in transition, and transitions define long-term returns.
Business Model
Patented prescription drugs
Biogen discovers and sells branded medicines for neurological diseases at premium prices.
Economic Engine
High-margin drug sales
Gross margins above 70 percent show the power of patented therapies.
Long-Term Lens
Pipeline renewal
The key question is whether new drugs can replace aging products over the next decade.
On this page
Company Story
How do Biogen Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“Biogen is a high-margin neuroscience specialist fighting revenue decline today to earn another decade of relevance through its pipeline.”
What does Biogen Inc. actually do?
Biogen researches, develops, and sells prescription drugs focused mainly on diseases of the brain and nervous system.
- Develops treatments for multiple sclerosis, Alzheimer’s disease, and other neurological disorders.
- Runs long and expensive clinical trials to win regulatory approval.
- Sells branded medicines to hospitals, insurers, and health systems worldwide.
Why it matters
Science drives the business
In biotech, one successful drug can generate billions, while failed trials can erase years of investment.
How does Biogen Inc. make money?
Biogen earns revenue by selling patented medicines at premium prices during their exclusivity period.
- Gross margin of 70.5 percent shows strong pricing power on approved drugs.
- Operating margin of 19.1 percent reflects heavy spending on research and development.
- Free cash flow equals 1.59 times net income, meaning reported profits turn into real cash.
Economic clue
Cash is real
Strong cash conversion gives Biogen flexibility to fund research and weather patent expirations.
Why do long-term investors keep Biogen Inc. on the radar?
Biogen operates in neurological diseases, an area with huge unmet need and aging demographics.
- Global populations are aging, increasing cases of Alzheimer’s and other brain disorders.
- Neurology drugs can command premium pricing if they show meaningful clinical benefit.
- High margins provide room to reinvest in the next generation of therapies.
Investor takeaway
A reinvention story
Revenue has shrunk by an average 2.8 percent over five years, so future value depends on new launches.
Based on company financial statements.
Benchmark Comparison
How has Biogen Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$682.91
-31.7% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| BIIB | -31.7% | $682.91 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Biogen Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to breakthrough neuroscience therapies with long patent protection.
- A profitable biotech with 70.5 percent gross margins and strong cash generation.
- A turnaround or renewal story where pipeline success could change the trajectory.
Be Careful If You Expect
- Steady, predictable revenue growth, five-year average revenue growth is negative 2.8 percent.
- Rising earnings momentum, earnings per share fell 21 percent year over year.
- A diversified product base without patent risk.
What To Watch Over Time
- Whether new neurology drugs can offset declines in older multiple sclerosis products.
- Operating margin trends, currently 19.1 percent and contracting.
- Sustained free cash flow above net income, currently 1.59 times net income.
Key Metrics
Which metrics matter most for Biogen Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
Negative 2.8% per year (5-year average)
Negative 4.0% per year (5-year average)
70.5% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | Negative 2.8% per year (5-year average) | Shows that the business has been shrinking slightly, highlighting the need for new products. |
| EPS Growth | Negative 4.0% per year (5-year average) | Earnings per share have declined over time, reflecting margin pressure and product headwinds. |
| Margin Quality | 70.5% gross margin | High gross margins show strong pricing power on patented drugs. |
Based on company financial statements.
Fundamentals
What do Biogen Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
9.7% ROIC
70.5% gross margin
20.9% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 9.7% ROIC | The business is currently showing poor capital efficiency. |
| Profitability | 70.5% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 20.9% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Biogen Inc.?
Biogen Inc. currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Biogen Inc.?
Company-specific questions readers often ask about Biogen Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Biogen develops and sells prescription medicines focused mainly on neurological diseases such as multiple sclerosis and Alzheimer’s.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Neurological diseases are growing with aging populations, and even modestly effective therapies can generate billions in annual sales due to high unmet need.
Gross margins above 70 percent provide ample room to reinvest in research while still generating a 20.9 percent free cash flow margin.
Deep expertise in multiple sclerosis and brain biology creates institutional knowledge that new entrants would struggle to replicate quickly.
Strong cash conversion, 1.59 times net income, gives Biogen resilience to fund long clinical programs without constant shareholder dilution.
Bear case
What can break
Patent expirations on key drugs can rapidly erode revenue, and five-year average revenue decline of 2.8 percent shows this risk is real.
Clinical trial failures in Alzheimer’s or other major programs could eliminate years of investment and damage credibility.
Drug pricing reform in the United States could compress margins, especially with net margin already at 13.2 percent and trending down.
Large pharmaceutical competitors with deeper pipelines could outspend and outmaneuver Biogen in neurology.
Risk Radar
Key Risks
Where downside pressure can build.
Product concentration risk, a handful of neurology drugs drive a large share of revenue, so loss of exclusivity could materially cut sales.
Margin compression risk, operating margin is 19.1 percent and contracting, which could pressure long-term earnings power.
Research risk, billions spent on trials may not produce approved drugs, leading to write-offs and lost time.
Pressure points
Concentration risk
Biogen has historically depended heavily on a small number of multiple sclerosis drugs for a large share of revenue. This concentration means that patent expirations or competitive launches can have an outsized impact on total sales and margins.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $184.87
- Daily move
- -1.71%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.